Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
-$0.03 today
- Market cap
- $372.57M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
Volume 0.17M
Average 0.97M
INDP Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Indaptus Therapeutics, Inc.NASDAQ: INDP
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns negative
Q1 FY2026 other income / expenses was -$381.48K, compared with $40.13K a year earlier. Trailing-twelve-month other income / expenses was -$1.44M.
Context
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$381.48K or moves back toward the trailing-twelve-month quarterly average of -$359.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (1.02M) USD
- Year-over-year change
- -395.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.02M) | -395.4% |
| FY2024 | 2024-12-31 | 343.72K | -64.0% |
| FY2023 | 2023-12-31 | 955K | +62.4% |
| FY2022 | 2022-12-31 | 588.11K | +3218.5% |
| FY2021 | 2021-12-31 | 17.72K | — |
Other Income / Expenses vs competitors
How INDP compares with its peers on the latest reported figures
- INDP's LTM Mar 2026 other income / expenses of -$1.44M is the lowest of the 2 companies compared; the peer median is $83.55K.
- Its year-over-year change of -681.1% is the lowest of 2, against a peer median of -95.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $83.55K | -95.8% | — | — | |
| LTM Mar 2026 | -$1.44M | -681.1% | — | — | |
| Peer median (excluding INDP) | $83.55K | -95.8% | — | — | |
Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.52M | 6.32M | 7.62M | 7.25M | 9.34M |
| Selling, General & Admin | 5.21M | 8.59M | 8.76M | 8.11M | 10.49M |
| Operating Expenses | 7.73M | 14.91M | 16.38M | 15.37M | 19.83M |
| Depreciation & Amortization | 1.4K | 1.78K | 1.28K | 735 | 0 |
| EBITDA | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.73M) | (14.91M) | (16.38M) | (15.37M) | (19.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17.72K | 588.11K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 17.72K | 588.11K | 955K | 343.72K | (1.02M) |
| Income Before Tax | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| EPS (Diluted) | (1.89) | (1.73) | (1.84) | (1.61) | (21.58) |
| Weighted Avg Shares | 4.09M | 8.26M | 8.4M | 9.36M | 966.12K |
| Weighted Avg Shares (Diluted) | 4.09M | 8.26M | 8.4M | 9.36M | 966.12K |
Indaptus Therapeutics, Inc.
NASDAQ:INDP
Intrinsic Alpha fair value
Locked
Current Price
$3.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.